Evidence map›Paper›PMID 26923014›Full record

ArticleJournal of Alzheimer's disease : JAD2016

Drivers: A Biologically Contextualized, Cross-Inferential View of the Epidemiology of Neurodegenerative Disorders.

Jesús de Pedro-Cuesta, Pablo Martínez-Martín, Alberto Rábano, Enrique Alcalde-Cabero, Fernando José García López, Javier Almazán-Isla, María Ruiz-Tovar, Maria-José Medrano, Fuencisla Avellanal, Olga Calero and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Risk of transmission of sporadic Creutzfeldt-Jakob disease by surgical procedures: systematic reviews and quality of evidence.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2017
    Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Jesús de Pedro-CuestaDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Pablo Martínez-MartínDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Alberto RábanoConsortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Enrique Alcalde-CaberoDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Fernando José García LópezDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Javier Almazán-IslaDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
María Ruiz-TovarDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Maria-José MedranoDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Fuencisla AvellanalDepartment of Applied Epidemiology, National Center for Epidemiology, Carlos III Institute of Health, Madrid, Spain.
Olga CaleroConsortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Miguel CaleroConsortium for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
Instituto de Salud Carlos III · ESBiomedical Research Networking Center on Neurodegenerative Diseases · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSutherland et al. (2011) suggested that, instead of risk factors for single neurodegenerative disorders (NDDs), there was a need to identify specific "drivers", i.e., risk factors with impact on specific deposits, such as amyloid-β, tau, or α-synuclein, acting across entities. OBJECTIVES AND

methodsRedefining drivers as "neither protein/gene- nor entity-specific features identifiable in the clinical and general epidemiology of conformational NDDs (CNDDs) as potential footprints of templating/spread/transfer mechanisms", we conducted an analysis of the epidemiology of ten CNDDs, searching for patterns.

resultsWe identified seven potential drivers, each of which was shared by at least two CNDDs: 1) an age-at-exposure-related susceptibility to Creutzfeldt-Jakob disease (CJD) and several late-life CNDDs; 2) a relationship between age at onset, survival, and incidence; 3) shared genetic risk factors for CJD and late-life CNNDs; 4) partly shared personal (diagnostic, educational, behavioral, and social risk factors) predating clinical onset of late-life CNDDs; 5) two environmental risk factors, namely, surgery for sporadic CJD and amyotrophic lateral sclerosis, and Bordetella pertussis infection for Parkinson's disease; 6) reticulo-endothelial system stressors or general drivers (andropause or premenopausal estrogen deficiency, APOEɛ4, and vascular risk factors) for late-life CNDDs such as dementia/Alzheimer's disease, type-2 diabetes mellitus, and some sporadic cardiac and vascular degenerative diseases; and 7) a high, invariant incidence ratio of sporadic to genetic forms of mid- and late-life CNDDs, and type-2 diabetes mellitus.

conclusionThere might be a systematic epidemiologic pattern induced by specific proteins (PrP, TDP-43, SOD1, α-synuclein, amyloid-β, tau, Langerhans islet peptide, and transthyretin) or established combinations of these.

Indexed as

AgingEnvironmentAge FactorsAmyloid Precursor Protein SecretasesApolipoproteins EAspartic Acid EndopeptidasesCreutzfeldt-Jakob SyndromeFemaleHumansIncidenceMaleNeurodegenerative DiseasesPersonalityRisk FactorsVascular DiseasesAmyloid Precursor Protein SecretasesApolipoproteins EAspartic Acid EndopeptidasesBACE1 protein, humanAmyloidepidemiologymethodsneurodegenerationrisk factors

Identifiers

PMID26923014
PMCPMC4927850
OpenAlexW2288959684

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.